BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

April 7, 2017
As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future. Prexton raised EUR 29 million via a series B financing earlier this year to progress foliglurax, a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM), into Phase II trials. A European Phase II trial is expected to enroll its first patient in June and will be completed by the end of 2018. A US trial is also planned. After Phase II, Conquet hopes the company will be able to license the compound to a big pharma for Phase III development.
Previous Video
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks t...

Next Article
Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress
Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress

An interview with Monica Weldon, President of Bridge the Gap – SYNGAP Education and Research Foundation Hou...